Balyasny Asset Management
MBIO icon

Balyasny Asset Management’s Mustang Bio MBIO Stock Holding History

Balyasny Asset Management’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42
Closed -$15K – 3039
2022
Q3 		$15K Buy
42
+24
+133% +$11.1K ﹤0.01% 2606
2022
Q2 		$8K Buy
+18
New +$9.96K ﹤0.01% 2605

Other funds holding MBIO

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Balyasny Asset Management's MBIO Position: Q4 2022 in Review

Balyasny Asset Management sold out of Mustang Bio (MBIO) in Q4 2022, closing a stake of 42 shares — an estimated $15K sold.

Balyasny Asset Management first reported a position in MBIO in Q2 2022 and held it in 2 quarters. The position peaked at $15K in Q3 2022. 60 funds tracked by Wall St. Rank hold MBIO as of Q4 2022.

  • Balyasny Asset Management reported no remaining Mustang Bio position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 42 Mustang Bio shares in Q4 2022, an estimated $15K.
  • Balyasny Asset Management first reported a position in Mustang Bio in Q2 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Mustang Bio position peaked at $15K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.